These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31220951)

  • 21. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.
    Núñez Galindo A; Macron C; Cominetti O; Dayon L
    Methods Mol Biol; 2019; 1959():89-112. PubMed ID: 30852817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.
    Ranganathan S; Nicholl GC; Henry S; Lutka F; Sathanoori R; Lacomis D; Bowser R
    Amyotroph Lateral Scler; 2007 Dec; 8(6):373-9. PubMed ID: 17852009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review).
    Król-Grzymała A; Sienkiewicz-Szłapka E; Fiedorowicz E; Rozmus D; Cieślińska A; Grzybowski A
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis.
    Byström S; Ayoglu B; Häggmark A; Mitsios N; Hong MG; Drobin K; Forsström B; Fredolini C; Khademi M; Amor S; Uhlén M; Olsson T; Mulder J; Nilsson P; Schwenk JM
    J Proteome Res; 2014 Nov; 13(11):4607-19. PubMed ID: 25231264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
    Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders.
    Khurana M; Rahman SO; Najmi AK; Pottoo FH; Akhtar MS
    Curr Protein Pept Sci; 2020; 21(12):1146-1163. PubMed ID: 33148155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
    Kroksveen AC; Jaffe JD; Aasebø E; Barsnes H; Bjørlykke Y; Franciotta D; Keshishian H; Myhr KM; Opsahl JA; van Pesch V; Teunissen CE; Torkildsen Ø; Ulvik RJ; Vethe H; Carr SA; Berven FS
    Proteomics; 2015 Oct; 15(19):3361-9. PubMed ID: 26152395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's and Parkinson's diseases: an environmental proteomic point of view.
    Demartini DR; Schilling LP; da Costa JC; Carlini CR
    J Proteomics; 2014 Jun; 104():24-36. PubMed ID: 24751585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study.
    Valko PO; Roschitzki B; Faigle W; Grossmann J; Panse C; Biro P; Dambach M; Spahn DR; Weller M; Martin R; Baumann CR
    J Sleep Res; 2019 Jun; 28(3):e12721. PubMed ID: 29961995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets.
    Mammana S; Fagone P; Cavalli E; Basile MS; Petralia MC; Nicoletti F; Bramanti P; Mazzon E
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29533975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.
    Opsahl JA; Vaudel M; Guldbrandsen A; Aasebø E; Van Pesch V; Franciotta D; Myhr KM; Barsnes H; Berle M; Torkildsen Ø; Kroksveen AC; Berven FS
    Proteomics; 2016 Apr; 16(7):1154-65. PubMed ID: 26841090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
    Kitamura Y; Usami R; Ichihara S; Kida H; Satoh M; Tomimoto H; Murata M; Oikawa S
    Neurol Res; 2017 Mar; 39(3):231-238. PubMed ID: 28107809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid cell-based therapies in neurological disorders: How far have we come?
    Böttcher C; Priller J
    Biochim Biophys Acta; 2016 Mar; 1862(3):323-8. PubMed ID: 26455341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).
    Maurer MH
    Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation.
    Koistinaho M; Koistinaho J
    Brain Res Brain Res Rev; 2005 Apr; 48(2):240-50. PubMed ID: 15850663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.